Guangding Biotech (6850) has officially received marketing authorization from the US Food and Drug Administration (FDA), which includes various models launched by Guangding Biotech after the establishment of the Qsep brand, including the standard laboratory Qsep100 biological analyzer, the basic laboratory Qsep400, the best choice for high-throughput analysis and the Qsep1 series, the best tool for on-site testing and point-of-care, have the opportunity to enter the US market, take advantage of the world's largest in vitro testing business opportunity, and add new growth engines for performance.
Share price of Guangding Biotechnology Co., Ltd. performed strongly today (9), hitting 60 yuan at one point, up more than 10%. The company is a developer of technical services and tools for the nucleic acid industry in Asia. In the fourth quarter of last year, it set a new record for the third consecutive month. The consolidated annual revenue reached 231 million yuan, which is also a new record at the same time, with an increase 29.1% a year.
Guangding Biotech said that since October last year, its revenue has been at a record high for three consecutive months. In December, its revenue reached an all-time high of 29.49 million yuan. The main growth spurt came from the core product of the Qsep series biological particle analyzer. The share of total revenue is about 80%. At present, Qsep series products have been sold to more than 50 countries. Therefore, the outstanding performance of revenue not only reflects demand in traditional peak seasons, but also. It has the added effect of launching your own brand.
Looking to the future, the company will continue to create more application opportunities for the Qsep series of biological fragment analyzers through the dual R&D teams of machines and reagents, while also developing patented instrument materials (cassettes) that meet the needs and needs of customers for Qsep. consumer goods will help and further expand the overall scope of income. We are optimistic that market demand will continue to be strong and that this year's operations have the potential to reach new heights.
Comments are closed.